Advertisement

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov December 1 2015 5 (12) 1225-1227; DOI:10.1158/2159-8290.CD-ITI5-12

In the Spotlight

Review

Research Briefs

  • Research Briefs
    RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
    Haiying Cheng, Yiyu Zou, Jeffrey S. Ross, Kai Wang, Xuewen Liu, Balazs Halmos, Siraj M. Ali, Huijie Liu, Amit Verma, Cristina Montagna, Abraham Chachoua, Sanjay Goel, Edward L. Schwartz, Changcheng Zhu, Jidong Shan, Yiting Yu, Kira Gritsman, Roman Yelensky, Doron Lipson, Geoff Otto, Matthew Hawryluk, Philip J. Stephens, Vincent A. Miller, Bilal Piperdi and Roman Perez-Soler
    Cancer Discov December 1 2015 5 (12) 1262-1270; DOI:10.1158/2159-8290.CD-14-0971

    Amplification of RICTOR is present in 8–13% of patients with lung cancer and is associated with a greater response to mTORC1/2 inhibition.

  • Research Briefs | AuthorChoice
    Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
    Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong and Ryan B. Corcoran
    Cancer Discov December 1 2015 5 (12) 1271-1281; DOI:10.1158/2159-8290.CD-15-0748

    Resistance to MET inhibition in MET-amplified esophagogastric cancer is mediated by KRAS mutation, coamplification of HER2 and/or EGFR, and intratumor heterogeneity in MET amplification.

Research Articles

  • Research Articles | AuthorChoice
    Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
    Elena Sotillo, David M. Barrett, Kathryn L. Black, Asen Bagashev, Derek Oldridge, Glendon Wu, Robyn Sussman, Claudia Lanauze, Marco Ruella, Matthew R. Gazzara, Nicole M. Martinez, Colleen T. Harrington, Elaine Y. Chung, Jessica Perazzelli, Ted J. Hofmann, Shannon L. Maude, Pichai Raman, Alejandro Barrera, Saar Gill, Simon F. Lacey, Jan J. Melenhorst, David Allman, Elad Jacoby, Terry Fry, Crystal Mackall, Yoseph Barash, Kristen W. Lynch, John M. Maris, Stephan A. Grupp and Andrei Thomas-Tikhonenko
    Cancer Discov December 1 2015 5 (12) 1282-1295; DOI:10.1158/2159-8290.CD-15-1020

    Alternative splicing of CD19 prevents its recognition by CD19-targeted chimeric antigen receptor (CAR) T cells and can underlie resistance to CD19 CAR T-cell therapy in patients with B-ALL.

  • Research Articles | AuthorChoice
    A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
    Anguraj Sadanandam, Stephan Wullschleger, Costas A. Lyssiotis, Carsten Grötzinger, Stefano Barbi, Samantha Bersani, Jan Körner, Ismael Wafy, Andrea Mafficini, Rita T. Lawlor, Michele Simbolo, John M. Asara, Hendrik Bläker, Lewis C. Cantley, Bertram Wiedenmann, Aldo Scarpa and Douglas Hanahan
    Cancer Discov December 1 2015 5 (12) 1296-1313; DOI:10.1158/2159-8290.CD-15-0068

    Integrated mRNA and miRNA profiling of mouse and human pancreatic neuroendocrine tumors (PanNET) identifies distinct subtypes and validates the RIP1-Tag2 mouse model as representative of human PanNET.

  • Research Articles
    Dual Roles of RNF2 in Melanoma Progression
    Kunal Rai, Kadir C. Akdemir, Lawrence N. Kwong, Petko Fiziev, Chang-Jiun Wu, Emily Z. Keung, Sneha Sharma, Neha S. Samant, Maura Williams, Jacob B. Axelrad, Amiksha Shah, Dong Yang, Elizabeth A. Grimm, Michelle C. Barton, Denai R. Milton, Timothy P. Heffernan, James W. Horner, Suhendan Ekmekcioglu, Alexander J. Lazar, Jason Ernst and Lynda Chin
    Cancer Discov December 1 2015 5 (12) 1314-1327; DOI:10.1158/2159-8290.CD-15-0493

    The prometastatic and oncogenic functions of RNF2 in melanoma are driven by differential changes in gene expression regulated by chromatin modification or recruitment of transcriptional activators, respectively.

  • Research Articles | AuthorChoice
    Infection Exposure Is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility
    Alberto Martín-Lorenzo, Julia Hauer, Carolina Vicente-Dueñas, Franziska Auer, Inés González-Herrero, Idoia García-Ramírez, Sebastian Ginzel, Ralf Thiele, Stefan N. Constantinescu, Christoph Bartenhagen, Martin Dugas, Michael Gombert, Daniel Schäfer, Oscar Blanco, Andrea Mayado, Alberto Orfao, Diego Alonso-López, Javier De Las Rivas, César Cobaleda, Maria Begoña García-Cenador, Francisco Javier García-Criado, Isidro Sánchez-García and Arndt Borkhardt
    Cancer Discov December 1 2015 5 (12) 1328-1343; DOI:10.1158/2159-8290.CD-15-0892

    Delayed exposure to infection promotes B-cell precursor acute lymphoblastic leukemia in the context of inactivating germline Pax5 mutations, which create an aberrant progenitor cell compartment that is susceptible to Jak3 mutation–induced transformation.

News in Brief

News in Depth

Research Watch

Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12

Sign up for alerts

Jump to

Advertisement